{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+for+maraviroc",
    "query": {
      "intervention": "placebo for maraviroc"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 20,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+for+maraviroc&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T00:14:50.481Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02519777",
      "title": "Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Placebo for maraviroc (MVC)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Maraviroc (MVC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 191,
      "start_date": "2016-04-21",
      "completion_date": "2021-01-05",
      "has_results": true,
      "last_update_posted_date": "2022-04-22",
      "last_synced_at": "2026-09-28T00:14:50.481Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • San Diego, California • Torrance, California + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02519777"
    },
    {
      "nct_id": "NCT02121795",
      "title": "Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "Allowed third antiretroviral agent",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF Placebo",
          "type": "DRUG"
        },
        {
          "name": "F/TAF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 668,
      "start_date": "2014-05-06",
      "completion_date": "2019-03-01",
      "has_results": true,
      "last_update_posted_date": "2020-03-12",
      "last_synced_at": "2026-09-28T00:14:50.481Z",
      "location_count": 57,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02121795"
    },
    {
      "nct_id": "NCT00098748",
      "title": "Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Optimized Background Therapy (OBT)",
          "type": "DRUG"
        },
        {
          "name": "maraviroc (UK-427,857)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2004-11",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2010-12-07",
      "last_synced_at": "2026-09-28T00:14:50.481Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098748"
    },
    {
      "nct_id": "NCT06511063",
      "title": "Antiviral Clinical Trial for Long Covid-19",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long Covid"
      ],
      "interventions": [
        {
          "name": "tenofovir disoproxil/emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "Selzentry",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2024-10-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-09-28T00:14:50.481Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06511063"
    },
    {
      "nct_id": "NCT03172026",
      "title": "Maraviroc to Augment Rehabilitation Outcomes After Stroke",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Maraviroc 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Rehabilitation therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "86 Years",
        "sex": "ALL",
        "summary": "30 Years to 86 Years"
      },
      "enrollment_count": 2,
      "start_date": "2019-08-01",
      "completion_date": "2020-10-01",
      "has_results": true,
      "last_update_posted_date": "2021-08-03",
      "last_synced_at": "2026-09-28T00:14:50.481Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • White Plains, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03172026"
    },
    {
      "nct_id": "NCT06974084",
      "title": "A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Long COVID"
      ],
      "interventions": [
        {
          "name": "Maraviroc (MVC)",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin, 10mg, 20mg, 40mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo, Maraviroc",
          "type": "DRUG"
        },
        {
          "name": "Placebo, Atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HealthBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 252,
      "start_date": "2026-07-15",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-09-28T00:14:50.481Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06974084"
    },
    {
      "nct_id": "NCT02469246",
      "title": "Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "ABC/3TC",
          "type": "DRUG"
        },
        {
          "name": "ABC/3TC Placebo",
          "type": "DRUG"
        },
        {
          "name": "F/TAF Placebo",
          "type": "DRUG"
        },
        {
          "name": "3rd ARV agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 567,
      "start_date": "2015-06-29",
      "completion_date": "2019-03-13",
      "has_results": true,
      "last_update_posted_date": "2019-10-25",
      "last_synced_at": "2026-09-28T00:14:50.481Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02469246"
    },
    {
      "nct_id": "NCT06853223",
      "title": "This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Graft Dysfunction",
        "Lung Transplantation",
        "Acute Lung Injury(ALI)",
        "Natural Killer Cell Mediated Immunity"
      ],
      "interventions": [
        {
          "name": "Maraviroc",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2025-12-07",
      "completion_date": "2028-08-14",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-09-28T00:14:50.481Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06853223"
    },
    {
      "nct_id": "NCT00735072",
      "title": "Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2008-09",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2020-08-17",
      "last_synced_at": "2026-09-28T00:14:50.481Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Stanford, California • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00735072"
    },
    {
      "nct_id": "NCT01505114",
      "title": "Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Maraviroc",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate",
          "type": "DRUG"
        },
        {
          "name": "Maraviroc placebo",
          "type": "OTHER"
        },
        {
          "name": "Emtricitabine placebo",
          "type": "OTHER"
        },
        {
          "name": "Tenofovir disoproxil fumarate placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 594,
      "start_date": "2012-06",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-09-28T00:14:50.481Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01505114"
    }
  ]
}